Bristol-Myers Squibb Co. (BMY): Price and Financial Metrics


Bristol-Myers Squibb Co. (BMY): $68.49

-0.82 (-1.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BMY POWR Grades


  • BMY scores best on the Value dimension, with a Value rank ahead of 97.04% of US stocks.
  • BMY's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • BMY's current lowest rank is in the Momentum metric (where it is better than 9.33% of US stocks).

BMY Stock Summary

  • With a market capitalization of $152,725,864,498, Bristol Myers Squibb Co has a greater market value than 98.52% of US stocks.
  • BMY's went public 35.6 years ago, making it older than 92.76% of listed US stocks we're tracking.
  • The volatility of Bristol Myers Squibb Co's share price is greater than that of merely 1% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Bristol Myers Squibb Co are AZN, LIN, AMGN, NEE, and SNY.
  • BMY's SEC filings can be seen here. And to visit Bristol Myers Squibb Co's official web site, go to www.bms.com.

BMY Valuation Summary

  • BMY's price/sales ratio is 3.6; this is 0% higher than that of the median Healthcare stock.
  • Over the past 243 months, BMY's price/earnings ratio has gone down 66.7.
  • BMY's price/earnings ratio has moved down 66.7 over the prior 243 months.

Below are key valuation metrics over time for BMY.

Stock Date P/S P/B P/E EV/EBIT
BMY 2016-08-18 5.6 6.6 34.2 26.9
BMY 2014-01-30 5.2 5.6 30.1 35.0
BMY 2005-07-28 2.6 4.7 25.1 16.3
BMY 2003-11-03 2.6 5.1 20.7 16.5
BMY 2003-05-28 2.7 5.2 32.3 22.9
BMY 2002-08-23 2.7 4.6 46.5 54.5

BMY Growth Metrics

  • The 5 year net income to common stockholders growth rate now stands at -46.25%.
  • The 4 year net income to common stockholders growth rate now stands at -39.39%.
  • The 2 year cash and equivalents growth rate now stands at 196.09%.
Over the past 34 months, BMY's revenue has gone up $21,210,000,000.

The table below shows BMY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 42,810 13,982 -6,219
2020-12-31 42,518 14,052 -9,015
2020-09-30 39,395 12,420 -44
2020-06-30 34,862 12,757 -563
2020-03-31 31,006 10,571 954
2019-12-31 26,145 8,067 3,439

BMY Price Target

For more insight on analysts targets of BMY, see our BMY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $75.37 Average Broker Recommendation 1.48 (Moderate Buy)

BMY Stock Price Chart Interactive Chart >

Price chart for BMY

BMY Price/Volume Stats

Current price $68.49 52-week high $69.34
Prev. close $69.31 52-week low $56.75
Day low $68.45 Volume 5,857,200
Day high $69.34 Avg. volume 11,051,853
50-day MA $66.77 Dividend yield 2.89%
200-day MA $63.67 Market Cap 152.19B

Bristol-Myers Squibb Co. (BMY) Company Bio


Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. BMS is one of the world's largest pharmaceutical companies, and is consistently ranked on the Fortune 500 list of the largest U.S. corporations. As of September 2020, it had the total revenue of $39.3 billion. (Source:Wikipedia)


BMY Latest News Stream


Event/Time News Detail
Loading, please wait...

BMY Latest Social Stream


Loading social stream, please wait...

View Full BMY Social Stream

Latest BMY News From Around the Web

Below are the latest news stories about Bristol Myers Squibb Co that investors may wish to consider to help them evaluate BMY as an investment opportunity.

12 Best Bear Market Stocks to Buy Now

In this article, we discuss the 12 best bear market stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Bear Market Stocks to Buy Now. The Centers for Disease Control and Prevention (CDC) in the United States on July 28 asked Americans who […]

Yahoo | July 31, 2021

Biogen: Does Aduhelm Make it the Next Dendreon?

Aduhelm was approved by the FDA, priced at $56,000/year, but it isn't a cure for Alzheimer's.

Dana Blankenhorn on InvestorPlace | July 30, 2021

15 Most Valuable Biotech Companies in the World

In this article we will take a look at the 15 most valuable biotech companies in the world. You can skip our detailed analysis of the biotechnology industry’s outlook for 2021, and some of the major growth catalysts for biotech stocks, and go directly to the 5 Most Valuable Biotech Companies in the World. Mankind […]

Yahoo | July 30, 2021

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy

PRINCETON, N.J., July 30, 2021--BMS Receives European Commission Approval for Opdivo As Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients....

Yahoo | July 30, 2021

Why Compugen Stock Is Rising Again Today

Shares of Compugen (NASDAQ: CGEN) were rising 4% as of 11:05 a.m. EDT on Thursday. The drugmaker's shares jumped on Wednesday after Compugen provided its second-quarter update. Compugen recently initiated patient dosing in three early stage studies evaluating experimental drug COM701.

Yahoo | July 29, 2021

Read More 'BMY' Stories Here

BMY Price Returns

1-mo 2.76%
3-mo 7.07%
6-mo 14.14%
1-year 18.30%
3-year 26.65%
5-year 25.44%
YTD 12.10%
2020 0.41%
2019 27.74%
2018 -12.90%
2017 7.71%
2016 -13.49%

BMY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full BMY Dividend History

Continue Researching BMY

Here are a few links from around the web to help you further your research on Bristol Myers Squibb Co's stock as an investment opportunity:

Bristol Myers Squibb Co (BMY) Stock Price | Nasdaq
Bristol Myers Squibb Co (BMY) Stock Quote, History and News - Yahoo Finance
Bristol Myers Squibb Co (BMY) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8286 seconds.